Busulphan and cyclophosphamide (Bu/CP) are widely used in preparative regimens for bone marrow transplantation. Many studies have shown a wide variation in busulphan pharmacokinetics. Moreover, higher rates of liver toxicity were reported in Bu/CP protocols than in a total body irradiation (TBI)-containing regimen. In the present paper we investigated the effect of the time interval between the last dose of busulphan and the first dose of cyclophosphamide on the pharmacokinetics of CP and its cytotoxic metabolite 4-hydroperoxycyclophosphamide (4-OHCP). Thirty-six patients undergoing bone marrow transplantation (BMT) were included in the study. We also investigated the occurrence of venoocclusive disease, mucositis and graft-versus-host disease. Ten patients conditioned with CP followed by TBI served as a control group (TBI). Twenty-six patients were conditioned with Bu/CP. The patients received Bu 
tautomeric form aldophosphamide and has been reported to cause cardiac toxicity leading to heart failure. 12, 13 Betaelimination of aldophosphamide results in the formation of PM and acrolein. Acrolein is the metabolite which is supposed to cause hemorrhagic cystitis. 14 The pharmacokinetics of 4-OHCP are formation rate limited. [15] [16] [17] It has been discussed whether 4-OHCP or PM is the major cytotoxic metabolite 18 and suggested that 4-OHCP passes through cell membranes and delivers polar PM into the cells. PM is then thought to be the ultimate alkylating agent in the cells and 4-OHCP acts as a transporter. 10 Metabolism of CP can be induced and reduced by many drugs and agents that influence the cytochrome P450 system. CP can also induce its own metabolism with repeated administration (autoinduction). 19, 20 The pharmacokinetics of CP and its metabolites show great inter-individual variability, which can affect treatment efficacy and toxicity. 16, 21, 22 CP and its metabolites undergo enzymatic detoxification to form inactive products. 23 , 24 The extent of metabolism depends, in part, on the activity and concentration of aldehyde dehydrogenase, glutathione (GSH) and glutathione S-transferase (GST). These may account for tissue selectivity, drug resistance and drugrelated toxicity. 25, 26 Many studies have shown the importance of GSH in the protection and detoxification of CP. 26, 27 GSH is also known to be involved in Bu clearance, which we have shown previously, [28] [29] [30] and recent studies have also shown that Bu is conjugated with GSH, a reaction which is mediated by GST. [31] [32] [33] The present investigation was designed to assess the effect of busulphan on the pharmacokinetics of CP and its metabolite 4-OHCP. We also studied the effect of the time interval between administration of Bu and CP on therapyrelated toxicity, ie mucositis, VOD, IP and graft-versushost disease (GVHD), since both drugs are highly metabolized via the liver. The overall aim of the study was to facilitate the design of an optimal dosing schedule for the combination busulphan and cyclophosphamide.
Patients and methods

Patients
Thirty-six patients undergoing allogeneic (BMT) or autologous (ABMT) bone marrow transplantation entered the study. The clinical data of the patients are listed in Table  1 . Ten patients conditioned with CP/TBI had a median age of 28 years, range 7-54 years. Twenty-six patients were conditioned in accordance with the Bu/CP protocol. They were divided into group A, who received their CP therapy less than 24 h after the last dose of busulphan (7-15 h) , and group B, who received their CP dose 24 h or more after the last dose of Bu (24-50 h). The median age of group A was 37 years (range 5-51) and of group B, 42 years (range 9-59). All patients had normal renal (serum creatinine Ͻ2.0 mg/dl) and hepatic (serum AST Ͻ0.6, ALT Ͻ0.6 kat/l and serum bilirubin Ͻ4 mol/l) functions. The local ethical committee of the Karolinska Institute approved the study design and informed consent was obtained from each patient.
Treatment and blood sampling
Cyclophosphamide (50-60 mg/kg) was administered as a 1-h constant infusion for 2 consecutive days. Blood samples were taken for the study only on the first day of CP therapy, ie before the infusion, at 5, 10, 30, 60 min during the infusion and 5,10, 20, 30 min and 1, 2, 4, 6, 12, 18 h after the infusion stopped. Blood samples were collected into cold heparinised tubes and immediately chilled on ice. The blood samples were centrifuged for 3 min at 3000 r.p.m. at 4°C and plasma was harvested. To stabilize 4-OHCP, 0.5 ml of plasma from each sample was transferred into a pre-chilled tube containing 1 ml of acetonitrile, vortexed and centrifuged for 3 min at 3000 r.p.m. at 4°C. The supernatant was transferred to a new tube and stored at −70°C, pending analysis. The busulphan dose was 1 mg/kg × 4 for 4 days. Blood samples were collected immediately before each dose during busulphan administration (dose 3-dose 16), to determine the mean minimum concentration of Bu (trough level). The blood was immediately centrifuged at 2000 g and plasma was frozen at −20°C until assay. Ondansetrone was used as the anti-emetic for all patients and diazepam as seizure prophylactic. None of the patients received phenytoin. Patients who were not treated with Bu, received 10-13 Gy TBI from a cobalt source in fractions over 3 days. Alternatively, 10 Gy TBI with the lungs shielded to receive no more than 9 Gy was delivered by a linear accelerator in a single dose.
Analytical methods
Sample work-up and analysis of CP: CP was measured by a slightly modified method based on the HPLC method described by Hardy et al. 34 Briefly, plasma was mixed with water and the internal standard (ifosphamide) was added. CP and the internal standard were separated from plasma proteins, using a Sep-Pak column. CP and the internal standard were eluted with methanol that was dried under a stream of nitrogen at 40°C. The residue was dissolved in water and extracted with dichloromethane. The dichloromethane phase was transferred to a tube, dried and the residue was reconstituted in the mobile phase and injected into the chromatographic system.
The analysis was run using HPLC with a UV-detector and a ODS Ultrasphere column. The absorbance was measured at 195 nm. The mobile phase contained a phosphate buffer (pH 4.0, 80%) and acetonitrile (20%), the flow rate was 1.0 ml/min. The calibration curve was linear between 3 and 160 g/ml.
Sample work-up and analysis of 4-OHCP: Prior to analysis samples were thawed, 1.0 ml supernatant was mixed with hydrochloric acid and 2,4-dinitrophenylhydrazine. The mixture was heated for 5 min at 50°C to form a 2,4-dinitrophenylhydrazone derivative with 4-OHCP, to stabilize and enhance its molar absorption. The 4-OHCP derivative was analyzed using a reverse-phase liquid chromatographic method as described previously. 35 The HPLC-system consisted of an octadecyl silica column, a pump and an UVdetector operating at 357 nm. The system was run in isocratic mode with phosphate buffer, pH 7, containing 40% RRT = regimen-related toxicity; MI = mucositis grade I; MII = mucositis grade II; MIII = mucositis grade III; VOD-I = mild form; VOD-II = moderate form; GVHD = graft-versus-host disease.
(v/v) acetonitrile, and a flow rate of 1.0 ml/min. The calibration curve was linear and ranged between 22-2180 ng/ml.
Busulphan determination:
After the addition of the internal standard (1,5-bis-methanesulfonoxy) pentane, busulphan and the internal standard were converted to 1,4 diiodobutane and 1,5 diiodopentane, respectively. Busulphan concentrations were determined using gas chromatography with electron capture detection as described previously. 36 
Diagnosis of VOD, mucositis and GVHD, including scoring of severity
VOD was diagnosed on the basis of clinical signs, ie presence of hyperbilirubinemia (total serum bilirubin Ͼ34 mol/l) and development of two of the following signs during the first 21 days post-transplant: weight gain Ͼ5% from preconditioning baseline weight, ascites and/or hepatomegaly. 37 VOD severity was graded as mild (self-limited and required no treatment), moderate (clinical abnormalities Bone Marrow Transplantation which required pain control and/or diuretics for fluid retention) and severe VOD (clinical abnormalities which required therapy and did not resolve by day 100 post transplant or ended in death). Mucositis was scored (I, II and III), according to Bearman. 9 The diagnosis and clinical grading of GVHD were based on Glucksberg's criteria. 38 Histological confirmation was obtained, as required.
Pharmacokinetic and statistical analysis
Pharmacokinetic modeling and parameter estimates were performed using WinNonlin ver. 3.0 (Pharsight, Mountain View, CA, USA). All pharmacokinetic data (ie both cyclophosphamide and 4-hydroxycyclophosphamide) for each patient were fitted simultaneously. All patients were fitted to a two compartment open model using the Gauss-Newton-Hartley algorithm. The areas under time-plasma concentration curves (AUC) were calculated using trapezoidal method while the elimination half-life was calculated from the slope of the terminal phase of elimination.
The mean, median and standard deviations were calcu-lated using GraphPad, InStat (version 3.0) and all values are presented as mean Ϯ s.d. Statistical analysis was performed using the Kruskal-Wallis test (non-parametric ANOVA) for comparing three groups and Mann-Whitney's U-test (non-parametric, unpaired, two-tailed) to compare two groups. Fisher's exact test was used to compare the incidence of VOD and occurrence of mucositis.
Results
All 36 patients had complete blood CP and 4-OHCP disposition curves from the first dose of CP. Plasma CP and 4-OHCP from patients fitted well with a two-compartment open model. Plasma concentration-time profiles from three patients representing different groups are shown in Figure 1a -c. After 60 min infusion, plasma CP and 4-OHCP disposition curves were parallel, which implies that the pharmacokinetics of 4-hydroxycyclophosphamide were formation-limited. The pharmacokinetic parameters for CP and 4-OHCP are listed in Table 2 . Since the bioavailability of 4-OHCP was unknown, only the apparent clearance (Cl 4-OHCP / F 4-OHCP ) and the apparent distribution volume (V 4-OHCP / F 4-OHCP ) could be estimated (values are not shown in Table 2 ).
The clearance of cyclophosphamide (Cl cp ) was 0.055 Ϯ 0.017 l/h/kg in CP/TBI patients which did not differ from that (0.055 Ϯ 0.010 l/h/kg) in patients who received their CP therapy 24 h or more (group B) after the last dose of Bu. However, CL CP was significantly (P = 0.003) lower in patients (group A) given CP less than 24 h after the last dose of Bu (0.036 Ϯ 0.014 l/h/kg) than in the other groups. A two-fold variation in clearance adjusted for body weight was observed in the TBI and B groups, while a 3.5-fold variation was found in the A group. The clearance of CP in the TBI and B groups was about 35% higher than in the A group. Two-to four-fold inter-individual variation was observed in the exposure to CP, expressed as AUC. The inter-individual variation was of the same order of magnitude in all groups. However, the elimination half-life of CP in group A was significantly (P = 0.002) longer (10.93 Ϯ 2.89 h) than in the B and TBI groups (7.09 Ϯ 1.51 vs 7.52 Ϯ 3.01 h, respectively). The maximum concentration of CP (390 g/ml) was significantly (P = 0.002) higher in group A than in the TBI and B groups (248 vs 200 g/ml, respectively). The distribution volume of CP was about 0.5 l/kg in all groups, which is in agreement with previously published results. 21, 25 No significant difference was found between the groups.
The exposure to the cytotoxic metabolite 4-OHCP, expressed as the AUC, was 40-60% lower in the A group than in the TBI and B groups. Since the bioavailability of 4-OHCP is not known, a better measure of exposure to the cytotoxic metabolite is the ratio AUC 4-OHCP /AUC CP . A significantly (P Ͻ 0.001) higher exposure to 4-OHCP was obtained in the B and TBI groups (0.013 and 0.012, respectively) than in group A (0.0053). No difference was seen between the TBI and B groups. The elimination halflife for 4-OHCP showed two-to four-fold variation within the groups. However, no significant difference was observed between the groups (the half-lives were 8.14, 10.10 and 8.88 h for group A, B and TBI, respectively).
The maximum concentration of 4-OHCP varied between 0.3-0.6% of that in CP. However, no difference was seen between the three groups. Plasma half-life values for 4- AUC CP = area under time-concentration curve of cyclophosphamide (g·h/ml); AUC 4-OHCP = area under time-concentration curve of 4-hydroxycyclophosphamide (g·h/ml); AUC 4-OHCP/CP = the ratio between area under time-concentration curve of 4-hydroxycyclophosphamide and cyclophosphamide; t. = elimination half-life (h); Cl = clearance (l/h/kg); Vss = distribution volume in l; Cmax = maximum reached concentration (g/ml).
hydroxycyclophosphamide increased approximately linearly, with an increase in plasma half-life values for cyclophosphamide in all groups. The slopes of these relationships were 0.68, 1.18 and 0.46 (TBI, B and A, respectively). The mean minimum concentration of busulphan (trough levels) during the steady-state level (based on 12-14 measured levels from dose 3 to dose 16) in group A was 670 Ϯ 305 ng/ml, which did not differ from that obtained in group B (693 Ϯ 190 ng/ml). However, a strong correlation Bone Marrow Transplantation (r 2 = 0.577, P = 0.004, Figure 2 ) between Bu concentration and AUC 4-OHCP was observed in patients in group A. Moreover, a significant correlation was seen between Bu concentrations and the ratio AUC 4-OHCP /AUC CP (representing exposure to the cytotoxic metabolite). However, no correlation was seen between AUC CP and busulphan concentrations during the steaty state. In patients in group B, no correlation between Bu concentration and AUC 4-OHCP , AUC CP or the ratio AUC 4-OHCP /AUC CP was found ( Figure  3 ). The incidence of VOD was significantly (P Ͻ 0.05) higher in group A (7/12 patients) than in the B and TBI groups (2/14 and 1/10, respectively). In the A group, five patients had moderate VOD and two had a mild form. In the B and TBI groups, VOD was classified as mild. Mucositis was also more frequent in group A (eight patients) than in the TBI (one patient) and B (one patient) groups. It was classified in all patients, except one, as grade I or II according to Bearman et al. 9 This patient (No. 19) in group A had a severe form of mucositis (grade III). No influence of age or diagnosis on the occurrence of VOD or mucositis was observed.
Discussion
Cyclophosphamide is a prodrug requiring activation by hepatic microsomal enzymes to its cytotoxic metabolites. CP pharmacokinetics are well studied. However, the kinetics of its first cytotoxic metabolite 4-OHCP are poorly documented because of its instability. Recently, analytical 16, 35 Despite the importance of 4-OHCP, its bioavailability (F 4-OHCP ) is still undefined and therefore its pharmacokinetic parameters are only assumptions (apparent values). 16, 17, 39 An important measure of the cytotoxic effect is the exposure to 4-OHCP, which can determine tumor response and adverse effects.
In the present study, we have shown that: (1) the interval between the last dose of busulphan and the first dose of cyclophosphamide has a great effect on the pharmacokinetics of CP and its metabolite 4-OHCP; (2) the exposure to the cytotoxic metabolite is altered in patients who received their CP therapy shortly after Bu treatment; (3) the AUC 4-OHCP and the ratio AUC 4-OHCP /AUC CP were positively correlated with busulphan concentrations at the steady-state level in patients who received their CP therapy in less than 24 h (group A) while no correlation was found in patients who received their CP therapy after 24 h (group B) and (4) we have also shown that the occurrence of regimen-related toxicity, such as veno-occlusive disease (VOD) and mucositis, depends on the interval between Bu and CP.
Ayash et al 12 have found an inverse correlation between cardiac toxicity and tumor response and cyclophosphamide AUC in breast cancer patients treated with high doses of cyclophosphamide, thiotepa and carboplatin. Slattery et al 16 have reported a negative correlation between AUC CP and AUC 4-OHCP in patients undergoing bone marrow transplantation and receiving busulphan and total body irradiation. Both authors suggested that a lower AUC CP might correlate with an increased conversion of CP to its cytotoxic metabolite 4-OHCP. In contrast, Sladek et al 15, 40 have concluded in two reports that the amount of 4-OHCP should be constant, ie the rate at which 4-OHCP is formed from CP. However, Chen et al 39 have recently reported a positive correlation between AUC CP and AUC 4-OHCP in patients receiving cyclophosphamide as a single agent.
In the present study, the disposition curves of CP and 4-OHCP were parallel (Figure 1 ) in all patient groups. We found a positive correlation between AUC CP and its elimination half-life values. A positive correlation was observed between the elimination half-lives of CP and 4-OHCP in all groups. These observations imply that the major determinant with regard to the half-life of 4-OHCP is its rate of formation rather than its clearance, which is in agreement with previously reported results. 15, 39, 40 When patient groups were analyzed separately, we did not find a negative correlation between AUC CP and AUC 4-OHCP , as reported by other investigators. 12, 16 However, analyzing the pooled data from all patients resulted in a significant negative correlation (P = 0.03). This was due to the low values of AUC 4-OHCP obtained in the patients in group A. TBI and B groups did not contribute to the negative correlation. Our results contrast with those reported previously. One major difference between the present group of patients and the study previously reported by Slattery et al 16 is that the patients in that study who received busulphan were also treated with phenytoin. Phenytoin is known to be a potent inducer of cytochrome P450, which is essential for CP metabolism. Ducharme et al 41 have reported an alteration in ifosphamide metabolism mediated by phenytoin.
Clinical pharmacokinetic studies have shown that the Bone Marrow Transplantation hepatic transformation of CP to its active cytotoxic metabolite 4-OHCP may be increased in cancer patients by the co-administration of many drugs, especially those which are inducers of human cytochrome P450, including phenytoin, phenobarbital, thiotepa and cimetidine. 39 Chang et al 42 have shown that in human liver, P450 enzyme CYP2B6 preferentially contributes to CP 4-hydroxylation, whereas CYP3A enhances ifosfamide 4-hydroxylation. Recently, some authors have reported 43 that 4-hydroxylation of cyclophosphamide and ifosfamide increased by about 200-400% when human hepatocytes were pretreated with phenobarbital, dexamethasone or rifampicin. In patients with normal hepatic and renal functions, a positive correlation between AUC CP and AUC 4-OHCP can be expected, 39 since the kinetics of 4-OHCP is formation-limited and the plasma AUC values of 4-OHCP increase with AUC of CP. However, a great interpatient variability in CP pharmacokinetics is reported, which subsequently can influence the formation of 4-OHCP and thus the therapeutic efficacy. This variability is dependent on many factors, including genetic polymorphism, liver status, coadministration of drugs that induce or inhibit cytochrome P450 enzymes, as well as repeated administration of CP, which induces its own metabolism. 10, 19, 20, 42 Coadministration of drugs that inhibit or induce specific cytochrome enzymes must be considered, since they affect the kinetics of 4-OHCP and CP.
Previous studies have shown that busulphan 28, 29, 44 is eliminated by an enzymatic reaction with glutathione to form a sulfonium ion of GSH in rat liver. Recent studies showed that human purified GST is an important catalyst for busulphan conjugation with GSH 32 and that busulphan is a better substrate for GST than other alkylating agents such as melphalan and chlorambucil. 31 In a recent publication, the same authors have reported that young children are more efficient metabolizers of busulphan than adults, which was suggested to be due to higher levels of GST in children than in adults. 45 The urinary metabolites isolated in man and rat 29, 46 suggested that the sulfonium ion must be decomposed in vivo, resulting in the formation of tetrahydrothiophene (THT). THT is a lipophilic compound and has to be oxidized before its excretion. The oxidation of THT was shown to yield THT-1 oxide, sulpholane and 3-hydroxysulpholane. These metabolites were isolated and identified in both rat and human. 29, 46 Damani and Houdi 47 have shown that cytochrome P450 can play an important role in the oxidation of THT and other xenobiotics containing sulfur. The oxidation of tetrahydrothiophene most probably occurs via the cytochrome P450 system. Sherratt and Damani 48 have reported that microsomal activity in rat hepatocytes declines by 35% of its baseline activity using THT as a substrate. Considering the high dose of Bu used clinically and the long exposure (4 days of treatment), Bu therapy undoubtedly can deplete GSH and GST levels. On the other hand, busulphan metabolites most probably inhibit cytochrome activity (Figure 4 ). An inhibition of the cytochrome probably reduces CP clearance and consequently the formation of 4-OHCP as that observed in group A patients.
Several studies have illustrated the critical importance of GSH as a determinant of cellular sensitivity to melphalan, cisplatin and cyclophosphamide [49] [50] [51] where GSH was rap- idly depleted by the administration of CP. 52 Cellular overexpression of glutathione content and glutathione S-transferase was also found to contribute to acquired resistance of tumor cells to 4-OHCP. 53 Yuan et al 54 have shown that GSH can form a conjugate with CP. Conjugation of the thiol group of GSH with acrolein is considered the main route of clearance of this highly toxic metabolic product. Gurtoo et al 52 noted a dose-dependent depletion of hepatic GSH by CP and its metabolite (acrolein). Cellular depletion of GSH content was correlated with an increase in 4-OHCP-induced cardiac cell toxicity 51 and acrolein induced cytotoxicity in pulmonary artery endothelial cells. 55 Schulman et al 56 have found that the treatment of dogs with BSO, a glutathione synthesis inhibitor, before treatment with alkylating agents caused a higher incidence of VOD, considered to be one of the lethal BMT complications. Hemorrhagic cystitis, a potentially life-threatening BMT complication connected with CP therapy, has been managed clinically by the use of sulfhydryl-containing compounds, such as Mesna.
14 Figure 2 shows a positive correlation between busulphan levels during the steady state and AUC 4-OHCP in group A. Also, a positive correlation was found between Bu levels and the ratio AUC 4-OHCP /AUC CP . In group B, however, no correlation was found between Bu levels and AUC 4-OHCP or AUC 4-OHCP /AUC CP (Figure 3 ). One explanation is that 4 days of high-dose Bu therapy most likely can deplete GSH and GST levels, which are involved in 4-OHCP detoxification. Increased levels of busulphan may reflect a decreased level of GST and hence an increase in the level of 4-OHCP. Such a correlation can be observed only when the levels of 4-OHCP are low (group A) and less marked in group B, since the levels of the CP metabolite are high.
In the present group of patients, a significant increase in the incidence of both VOD and mucositis were observed in patients who received their CP therapy in less than 24 h, unlike in the TBI group, and those patients who received their CP therapy 24 h or more after the last dose of busulphan. This was presumably due to the cellular depletion of GSH caused by Bu and subsequently a secondary depletion caused by CP administration. Exposure of the glutathione depleted hepatocytes and mucosa to a low concentration of 4-OHCP and acrolein may contribute to both VOD and mucositis. Three cases of mild GVHD occurred in group A patients (patients Nos 16, 17, 20) and one patient in each of the other groups (patients Nos 4 and 26). This was probably due to the low exposure to the cytotoxic metabolite 4-OHCP and consequent low immunosuppressive effect.
This study demonstrates that the short interval between the last dose of Bu and first dose of CP negatively influences the pharmacokinetics of cyclophosphamide. Since the clearance of busulphan is determined principally by hepatic metabolism involving both GST and GSH, which also contribute a great deal to CP detoxification, it seems likely that cellular depletion of GSH is difficult to avoid. This can have clinically important effects on cyclophosphamide and its cytotoxic metabolite 4-hydroxycyclophosphamide and thus both their therapeutic efficacy and side-effects. The results of the present study have raised an important question: can we optimize preparative regimen administration protocols in relation to both time schedules and dose intensity to obtain higher efficacy and less therapy-related toxicity? More detailed studies on the pharmacokinetics and pharmacodynamics are needed to optimize and define the relation between alkylating agents, especially cyclophosphamide and its metabolites, with other cytochrome P450-dependent drugs, as well as with glutathione and glutathione S-transferases.
